The Evaluation of Interstitial Abnormalities in Group B of the 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Classification of Chronic Obstructive Pulmonary Disease (COPD)

Masahiro Ohgiya, Hirotsushi Matsui, Atsuhisa Tamura, Takafumi Kato, Shinobu Akagawa and Ken Ohta

Abstract:
Objective  In 2011, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification categorized chronic obstructive pulmonary disease (COPD) patients into 4 groups. A report demonstrated that the mortality in Group B was higher than that in Group C. Ischemic heart disease and cancer were suggested to be the cause. The aim of the present study was to test the hypothesis that interstitial lung abnormalities (ILAs) are more prevalent in Group B than Group C and that they may be responsible for the higher mortality in Group B.

Methods  Patients were selected based on their pulmonary function test results. The inclusion criterion was a forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) of <70% after the inhalation of a bronchodilator. Patients without a smoking history or computed tomography (CT) scan were excluded. The medical records of the patients were retrospectively reviewed, and the selected patients were categorized into Groups A to D. High-resolution CT scans were used to investigate the presence of ILAs and determine the low attenuation area (LAA).

Results  Among the 349 COPD patients, ILAs were detected in 10.3% of the patients in Group A, 22.5% of the patients in Group B, 5.6% of the patients in Group C, and 23.1% of the patients in Group D. In Group B, the frequency of ILAs was significantly higher and the area affected by the ILAs was significantly greater in comparison to Group C. Among the patterns of interstitial abnormalities, the area of honeycombing in Group B was significantly greater than that in Group C. Furthermore, among the patients in Group B, the LAA in the ILA-positive patients was significantly greater than that in the ILA-negative patients.

Conclusion  In Group B, the area occupied by ILAs-especially honeycombing-was greater than that in Group C. This contributed to the preserved %FEV1, and possibly to the poorer prognosis of the patients in Group B.

Key words: COPD, CPFE, interstitial lung abnormalities

(Intern Med 56: 2711-2717, 2017)  
(DOI: 10.2169/internalmedicine.8406-16)

Introduction

In 2011, the Global Initiative for Chronic Obstructive Lung Disease (GOLD), in collaboration with the National Heart, Lung, and Blood Institute, National Institutes of Health, and the World Health Organization, proposed a new system for the classification of chronic obstructive pulmonary disease (COPD), which was included in the national guidelines. COPD was classified into four categories, A-D, based on the level of risk as defined by the degree of airflow limitation and the frequency of acute exacerbations, and the severity of the symptoms, as defined by the dyspnea scale of the modified British medical research council...
dyspnea scale (mMRC) and a COPD assessment test (CAT) (1, 2).

In 2012, Lange et al. determined the prognosis of COPD patients in each category of the 2011 GOLD classification and also in Stage 1 to 4 of the 2007 GOLD classification (3). The authors concluded that the mortality of Group B patients with more symptoms and a better percent predicted forced expiratory volume in 1 second (%FEV1) value was higher in comparison to Group C patients who showed fewer symptoms and worse %FEV1 values because a Group B classification was more frequently associated with ischemic heart disease and malignancy (4, 5).

On the other hand, comorbid interstitial pneumonia, which was not evaluated closely in the above studies, might affect the %FEV1 and a patient’s symptoms (6-8). Interstitial abnormalities, if present in emphysematous lungs, could increase the %FEV1 value, the dyspnea score, and the mortality of the COPD patients (9). We, therefore, evaluated the interstitial lung abnormalities (ILAs) in each category of COPD to test the hypothesis that the frequency and severity of ILAs might be higher in comparison to Group C.

### Materials and Methods

**Patient selection and classification (Fig. 1)**

The study population included patients whose FEV1/forced vital capacity (FVC) value was <70% after bronchodilator inhalation and who were treated from January 2011 to July 2014. Patients without a history of smoking, patients with bronchial asthma and patients for whom computed tomography (CT) scans had not been performed were excluded from the study (10). When more than one pulmonary function test was performed, the one performed closest (in time) to the CT scan was selected. Patient confidentiality was maintained.

GOLD 2011 classified COPD patients into 4 groups based on risk, as determined by the %FEV1 value and/or the frequency of acute exacerbations, and the severity of symptoms as assessed by the mMRC and/or the CAT score. In this study, the risk was estimated based on the %FEV1 alone and not by the incidence of acute exacerbations. The present study was retrospective in nature; thus, we could not check all of the events related to a patient’s acute exacerbations in their medical records. Symptoms were determined by the mMRC scale because the CAT score was not available for most of the patients.

**The assessment of emphysema and interstitial abnormalities**

Emphysematous changes were evaluated on a high resolution CT (HRCT) scan according to Goddard’s method (11) with modifications; the percentage of the low attenuation area (LAA) was estimated by two independent pulmonologists and scored as 0 (0-10% LAA) to 9 (90-100% LAA) on 3 planes (at the level of aortic arch, the carina, and 2 cm above the right diaphragm) on each side of the lung. ILAs were estimated on HRCT images on 4 planes; these included the three above-mentioned planes and a plane under the top of the right diaphragm, which was incorporated for the estimation of the area of the ILA, similar to a previous report (12). The percent area of the ILA on the 4 planes on both sides was estimated by two independent pulmonologists and scored from 0 (0-10% ILA) to 9 (90-100% ILA). The severity of the ILAs was classified into 4 groups: very mild (average score of 4 planes ≤ 1), mild (≤ 2), moderate (3-4), and intense (>4) (Table).

The patterns of ILA, i.e. honeycombing, reticular abnormalities and ground glass opacities, and their percent area were also evaluated on the same planes (Fig. 1b). When the two pulmonologists did not agree, their scores were averaged. In addition, interstitial lung abnormalities were also assessed according to the serum levels of Krebs von den Lungen (KL)-6.

**Statistical analysis**

The Prism (Ver.5) software program (GraphPad Software CA, USA) was used for the statistical analysis. The Mann-Whitney test, $\chi^2$ test, and an analysis of variance (ANOVA) were performed as appropriate.

**Compliance**

Our study is performed in accordance with the principles of the Declaration of Helsinki and was approved by the ethics committee of our hospital.

**Results**

**The patient profiles**

Among the 645 patients with airflow limitation (FEV1/FVC<70%), 349 patients were finally evaluated in the present study (Fig. 1a). These patients were categorized into Group A (n=181), Group B (n=75), Group C (n=49), and Group D (n=44). The mMRC scores and %FEV1 values of each category are shown in Fig. 2. The mMRC dyspnea scale was highest in Group D and lowest in Group C. The %FEV1 value decreased according to the patient’s classification from Group A to D, while the LAA increased. Although the frequency of acute exacerbations was not evaluated for the COPD classification in this study, to the best of our knowledge, none of the patients in this study experienced more than one acute exacerbation. None of the COPD patients with ILAs received antifibrotic drugs or glucocorticosteroids for the treatment of interstitial pneumonia. Our review of the medical records in Group B revealed that 8 patients (10.7%) had acute coronary syndrome and 10 patients (13.3%) had lung carcinoma.

**The evaluation of the ILAs in each of the COPD groups (Fig. 3)**

ILAs were detected in 10.3% of the patients in Group A,
Figure 1. The method of patient selection and categorization. (a) After selecting the patients with a post-bronchodilator FEV₁/FVC value of <70%, patients without a history of smoking, patients with bronchial asthma and patients who did not undergo a CT scan were excluded. The areas of low attenuation and interstitial lung abnormalities were evaluated. A total of 349 patients were included and were subsequently categorized into 4 groups based on their degree of risk and the severity of their symptoms. CT: computed tomography, mMRC: the Modified British Medical Research Council dyspnea scale, %FEV₁: percent predicted forced expiratory volume in 1s, FVC: forced vital capacity. (b) Representative pictures of the patterns of ILA (honeycombing, reticular abnormalities and ground glass opacities).

Table. The Profiles of the Patients in Each Group.

|                  | A     | B     | C     | D     |
|------------------|-------|-------|-------|-------|
| Number of patients | 181   | 75    | 49    | 44    |
| Age (years old)  | 68.9±10.8 | 75.2±9.9 | 69.0±10.9 | 74.0±7.4 |
| BMI              | 22.5±3.4 | 23.1±3.7 | 21.9±3.7 | 20.3±3.0 |
| ILA degree of severity |   |   |   |   |
| Very mild        | 9     | 8     | 3     | 10    |
| Mild             | 10    | 5     | 0     | 0     |
| Moderate         | 1     | 2     | 0     | 0     |
| Intense          | 0     | 2     | 0     | 0     |
Figure 2. The symptom severity, airflow limitation, and emphysematous changes among the four groups. (a) The severity of the symptoms was classified according to the mMRC score (0-4) four groups. (b) The %FEV_{1} values of the four groups. (c) The magnitude of the low attenuation area (according to the LAA score) in the four groups. The Kruskal-Wallis test was used to test the statistical significance of the differences. *p<0.05, **p<0.01. mMRC: the Modified British Medical Research Council dyspnea scale, %FEV_{1}: percent predicted forced expiratory volume in 1 s, LAA: low attenuation area

22.5% of the patients in Group B, 5.6% of the patients in Group C, and 23.1% of the patients in Group D. Among the COPD patients with ILAs, the serum level of KL-6 was 353.2±148.5 (U/mL) in the very mild group (n=21), 631.7±513.6 (U/mL) in the mild group (n=10), 408.8±208.4 (U/mL) in the moderate group (n=4), and 963.0±956.0 (U/mL) in the intense group (n=2). The severity of the ILAs was highest in Group B and lowest in Group C. The frequency and severity of the ILAs were significantly higher in Group B than in Group C. The patterns of ILA were classified as honeycombing, reticular abnormalities or ground glass opacities. The prevalence of each ILA pattern and the corresponding degree of severity are shown in Fig. 3. In the Group B patients, honeycombing and reticular abnormalities were detected more frequently and in a wider area in comparison to the Group C patients. In contrast, the rates at which ground glass opacities and their degree of severity were similar in all 4 groups.

The effects of ILAs among the patients in Group B (Fig. 4)

In the Group B patients, patients with ILAs demonstrated greater %FEV_{1} values and higher LAA scores than patients without ILAs; however, this result did not reach statistical without significance. A significant difference was observed in the LAA scores of patients with and without honeycombing, suggesting that the airflow limitation associated with large LAAs might be neutralized by honeycombing, but not by reticular abnormalities or ground glass opacities.

Discussion

Combined pulmonary fibrosis and emphysema (CPFE) was first proposed as idiopathic pulmonary fibrosis with emphysematous change (13) and was then expanded to encompass the pulmonary diseases of smokers with airflow obstruction, emphysematous changes, and pulmonary fibrosis (9, 14). In this study, we first selected patients with COPD and then examined their HRCT scans to investigate their ILAs. Since even the slightest ILAs were included in this study, many of the COPD patients with ILAs only exhibited “very mild” to “mild”, subclinical interstitial changes that were often not visible on chest X-rays. Although CPFE is not defined strictly, these patients were considered to have COPD with ILAs in the present study. The differences in the clinical course and the pathophysiology between CPFE and COPD with ILAs were beyond the scope of this study. Among the 349 COPD patients, 47 patients (13.5%) ex-
The frequency, area and patterns of interstitial lung abnormalities in Groups A-D. (a) The prevalence of interstitial lung abnormalities was investigated in each group of COPD patients. (b) The area of interstitial lung abnormalities was evaluated as the ILA score in each group of COPD patients. (c) The prevalence of honeycombing in each group of COPD patients. (d) The area of honeycombing (evaluated as the ILA score) in each group of COPD patients. (e) The prevalence of ground glass opacities in each group of COPD patients. (f) The area of ground glass opacity (evaluated as the ILA score) in each group of COPD patients. (g) The prevalence of reticular shadow in each group of COPD patients. (h) The area of reticular shadow, evaluated as the ILA score in each group of COPD patients. Error bars indicated standard errors of the mean. *p<0.05, **p<0.01. mMRC: the Modified British Medical Research Council dyspnea scale, %FEV1: percent predicted forced expiratory volume in 1 s, ILA: interstitial lung abnormalities, COPD: chronic obstructive pulmonary disease.
of their better %FEV1 values and higher mMRC scores, who are prone to be categorized into Group B because 2-3 years after their diagnosis; thus, their prognosis is worse in addition, patients with IPF are expected to survive for 2-3 dependent factor that predicted a poor prognosis (14, 19). In the coexistence of fibrosis and emphysema was an inde-
comorbid ischemic heart disease, malignant tumors (3), as well as mental disorders (i.e. anxiety or depression) and osteoporosis) (17). We would add the presence of ILAs as another reason for the shorter life of the Group B patients. In a previous study, 35% of patients with idiopathic pulmonary fibrosis (IPF) exhibited emphysematous change, leading to a poorer prognosis, partly due to pulmonary hypertension (9, 14, 17, 18). There is also a report suggesting that the coexistence of fibrosis and emphysema was an independent factor that predicted a poor prognosis (14, 19). In addition, patients with IPF are expected to survive for 2-3 years after their diagnosis; thus, their prognosis is worse than COPD alone (20, 21). COPD patients with honeycombing, who are prone to be categorized into Group B because of their better %FEV1 values and higher mMRC scores, might have contributed to the poorer prognosis of the Group B patients.

This study is associated with three limitations. First, since patients were selected from a list of patients who underwent pulmonary function tests, some of the most severe patients without recent pulmonary function tests were not included in this study. Second, some important data were missing from this cross-sectional retrospective study (e.g. DLco, CAT, the frequency of acute exacerbations). Although we checked the medical records for comments about acute exacerbations of COPD and found no patients with two or more exacerbations in one year, we were of the opinion that the data would have underestimated their frequency. Finally, we could not determine the prognosis of the patients with and without ILAs. A longitudinal or prospective study might be needed to clarify this point.

In conclusion, since the presence of ILAs helped to preserve the %FEV1 value in COPD patients, ILAs, especially honeycombing, were most prevalent in Group B of the 2011 GOLD classification. We suspect that this would explain why the prognosis of Group B was poorer in comparison to Group C.

The authors state that they have no Conflict of Interest (COI).

References

1. Global initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management, and prevention of
chronic obstructive pulmonary disease: revised 2011.

2. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 176: 532-555, 2007.

3. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification. Am J Respir Crit Care Med 186: 975-981, 2012.

4. Lange P, Mogelvang R, Marott JL, Vestbo J, Jensen JS. Cardiovascular morbidity in COPD: a study of general population. COPD 7: 5-10, 2011.

5. Brekke PH, Omland T, Smith P, Søyseth V. Underdiagnosis of myocardial infarction in COPD - Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation. Respir Med 102: 1243-1247, 2008.

6. Washko GR, Hunninghake GM, Fernandez IE, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med 364: 897-906, 2011.

7. Doherty MJ, Peterson MG, O’Grady EA, Pellegrini V, Calverley PM. Cryptogenic fibrosing alveolitis with preserved lung volumes. Thorax 52: 998-1002, 1997.

8. Japanese Guidelines for COPD Diagnosis and Management. 4th ed. Nagai A, Kurosawa H, Nishimura M, et al. The Japanese Respiratory Society, Tokyo, 2014: 25.

9. Ryerson CJ, Hartman T, Elicker BM, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest 144: 234-240, 2013.

10. Mathieson JR, Mayo JR, Staples CA, Müller NL. Chronic diffuse infiltrative lung disease: comparison of diagnostic accuracy of CT and chest radiography. Radiology 171: 111-116, 1989.

11. Goddard PR, Nicholson EM, Laszlo G, et al. Computed tomography in pulmonary emphysema. Clin Radiol 33: 379-387, 1982.

12. Kazerooni EA, Martinez FJ, Flint A, et al. Thin-section CT obtained at 10-mm incre, emts versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. Am J Roentgenol 169: 977-983, 1997.

13. Wiggins J, Strickland B, Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respiratory Med 84: 365-369, 1990.

14. Kitaguchi Y, Fujimoto K, Hanaoka M, Honda T, Hotta J, Hirayama J. Pulmonary function impairment in patients with combined pulmonary fibrosis and emphysema with and without airflow obstruction. Int J Chron Obstruct Pulmon Dis 9: 805-811, 2014.

15. Cottin V. The impact of emphysema in pulmonary fibrosis. Eur Respir Rev 22: 128, 153-157, 2013.

16. Cottin V, Nuens H, Brillet PY, et al; Grouped’Etude. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 26: 586-593, 2005.

17. Gruffydd-Jones K. GOLD guidelines 2011: what are the implications for primary care? Prim Care Respir J 21: 437-441, 2012.

18. Seung HC, Lee HY, Lee KS, et al. The value of CT for disease detection and prognosis determination in combined pulmonary fibrosis and emphysema (CPFE). PLoS ONE 9: e107476, 2014.

19. Schwartz DA, Fossen DSV, Davis DS, et al. Determinants of progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 149: 444-449, 1994.

20. Brett L, Harold RC, Talmadge EKJ, et al. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183: 431-440, 2011.

21. Athol UW, Sujal RD, Michael BR, et al. Idiopathic pulmonary fibrosis. A composite physiologic index derived from disease extent observe by computed tomography. Am J Respir Crit Care Med 167: 962-969, 2003.

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).